Promis Diagnostics’ EarlyTect BCD Receives FDA Breakthrough Device Designation for Bladder Cancer Detection

With Breakthrough Device Designation, EarlyTect BCD could become available as a new diagnostic option sooner for people suspected of having bladder cancer IRVINE, Calif., April 28, 2023 /PRNewswire/ — Promis Diagnostics, Inc. today announced that the U.S. Food and Drug Administration…